Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 23;151(1):43.
doi: 10.1007/s00432-025-06089-x.

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

Satoshi Endo  1 , Hisao Imai  2   3 , Atsuto Mouri  4   5 , Kasumi Tsukamoto  5 , Kenji Masaki  4 , Kosuke Hashimoto  4 , Yu Miura  4 , Ayako Shiono  4 , Ou Yamaguchi  4 , Junichi Nakagawa  6 , Kyoichi Kaira  4   6 , Kunihiko Kobayashi  4 , Hiroshi Kagamu  4
Affiliations

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

Satoshi Endo et al. J Cancer Res Clin Oncol. .

Abstract

Purpose: Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficacy and safety of first-line Nivo-Ipi therapy in elderly patients with NSCLC.

Methods: This retrospective study included 57 patients with NSCLC (52 men and 5 women), aged ≥ 75 years (range: 75-86) who received first-line Nivo-Ipi therapy from December 2020 to November 2022 at four institutes in Japan. Patient characteristics, therapeutic efficacy, and the incidence and severity of adverse events (AE) were assessed.

Results: The overall response rate was 42.1%, the disease control rate was 73.6%, the median progression-free survival (PFS) was 7.1 months, and the median overall survival (OS) was 14.1 months. Common Grade ≥ 3 AEs included pneumonitis, elevated aspartate transaminase, elevated alanine transaminase, adrenal insufficiency, and colitis. No treatment-related deaths were reported. PFS and OS were longer in patients who experienced treatment-related AEs. Patients with and without AEs had a median PFS of 11.7 and 2.8 months, respectively. Similarly, the median OS of patients with and without AEs was 20.4 and 9.0 months, respectively.

Conclusion: First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatment-related AEs was associated with improved clinical outcomes, suggesting a potential prognostic value of AEs in this population.

Keywords: Advanced non-small cell lung cancer; Elderly patients; First-line treatment; Immune checkpoint inhibitor; Ipilimumab; Nivolumab.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interests: The authors declare no competing interests. Ethics Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the International Medical Center, Saitama Medical University (number 2023-080). Consent to participate: The need for informed consent was waived by the institutional review boards of the participating institutions owing to the retrospective nature of the study. However, an opportunity to refuse participation through the opt-out method was provided. Consent to publish: Not applicable.

Figures

Fig. 1
Fig. 1
a A Kaplan–Meier analysis of the progression-free survival among the 57 patients. The median progression-free survival after the initiation of first-line nivolumab and ipilimumab was 7.1 (95% confidence interval: 4.8–11.0) months. PFS progression-free survival. b A Kaplan–Meier analysis of the overall survival among the 57 patients. The median overall survival after the start of first-line nivolumab and ipilimumab was 14.1 (95% confidence interval: 9.1–20.4) months
Fig. 2
Fig. 2
Progression-free survival (PFS) and overall survival (OS) based on treatment-related AEs. a PFS: With AEs, median PFS = 11.7 months; PFS: without AEs, median PFS = 2.8 months b OS: With AEs, median OS = 20.0 months; OS: without AEs, median OS = 9.1 months
See this image and copyright information in PMC

References

    1. Ahmed T, Lycan T, Dothard A et al (2020) Performance status and age as predictors of immunotherapy outcomes in advanced non-small-cell lung cancer. Clin Lung Cancer 21:e286–e293. 10.1016/j.cllc.2020.01.001 - DOI - PMC - PubMed
    1. Akamatsu H, Murakami E, Oyanagi J et al (2020) Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist 25:e679–e683. 10.1634/theoncologist.2019-0299 - DOI - PMC - PubMed
    1. Albiges L, Tannir NM, Burotto M et al (2020) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5:e001079. 10.1136/esmoopen-2020-001079 - DOI - PMC - PubMed
    1. Blazek J, Hosek P, Hrabcova K et al (2023) Serious immune-related adverse events are associated with greater efficacy of nivolumab therapy against non-small cell lung cancer. In Vivo 37:2229–2236 - DOI - PMC - PubMed
    1. Blum SM, Rouhani SJ, Sullivan RJ (2023) Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev 318:167–178. 10.1111/imr.13262 - DOI - PubMed

MeSH terms

LinkOut - more resources